Claims
- 1. A peptide of the formula I ##STR5## in which X is hydrogen or (C.sub.1 -C.sub.7)-acyl or, if A represents pyroglutamyl, is absent;
- A is Pgl, dehydro-Pro, Pro, D-Thi, D-Pgl or D-Nal(2) optionally substituted in the aromatic ring by one or two identical or different radicals from the series bromo, chloro, fluoro, nitro, amino, methyl and methyoxy, D-Phe substituted in this way or D-Trp substituted in this way;
- B in His or D-Phe optionally substituted in the phenyl ring by one or two identical or different radicals from the series bromo, chloro, fluoro, nitro, amino, methyl and methoxy;
- C is Trp, D-Thi-D-Pal(3) or D-Trp optionally substituted in position 5 and/or 6 by one or two identical or different radicals from the series bromo, chloro, fluoro, nitro, amino, methyl or methoxy;
- D is Tyr, Arg or His;
- E is D-Ser(R.sup.1), .beta.-Asn, .beta.-Asp-Ome, D-Thi or the radical of A D-Amino acid of general formula II; ##STR6## F is Ser(R.sup.1), Leu, Trp or Phe; G is Gly-NH.sub.2, Aza-Gly-NH.sub.2, D-Ala-NH.sub.2 or NH-(C.sub.1 -C.sub.4)-alkyl;
- R.sup.1 is optionally partly protected glycosyl radical with at least one free hydroxyl group and
- R.sup.2 is hydrogen, (C.sub.1 -C.sub.4)-alkoxycarbonyl, (C.sub.1 -C.sub.4)-alkoxy, (C.sub.1 -C.sub.4)-alkyl which is optionally monosubstituted by (C.sub.1 -C.sub.4)-alkoxycarbonyl or (C.sub.1 -C.sub.4)alkoxycarbonylamino, phenyl which is optionally substituted by up to three identical or different radicals from the series chloro, fluoro, methyl and (C.sub.1 -C.sub.4)-alkoxy, naphthyl, 4, 5,6,7-tetrahydrobenzimidazol-2-yl or indolyl, or a physiologically acceptable salt thereof, with the proviso that
- a) if E represents a residue of the formula II,.beta.-Asn, .beta.-Asp-OMe or D-Thi, F is exclusively Ser(R.sup.1) and
- b) if F represents Leu, Phe or Trp, E is exclusively D-Ser(R.sup.1).
- 2. A peptide of the formula I as claimed in claim 1, wherein
- X is absent;
- A is Pgl;
- B is His;
- C is Trp;
- D is Tyr or His;
- E is D-Ser(R.sup.1), .beta.-Asn, .beta.-Asp-Ome or the residue of a D-amino acid of the formula II;
- F is Ser(R.sup.1), Trp or Leu and
- G is Gly-NH.sub.2, Aza-Gly-NH.sub.2 or NH-(C.sub.1 -C.sub.4)-alkyl and
- R.sup.1 and R.sup.2 are defined in claim 1, or a physiological acceptable salt thereof.
- 3. A peptide of the formula I as claimed in claim 1, wherein
- X is hydrogen or (C.sub.1 -C.sub.7)-acyl or is absent,
- A is dehydro-Pro, Pro, D-Thi, D-Pgl, optionally substituted D-Nal(2), optionally substituted D-Phe or optionally substituted D-Trp;
- B is optionally substituted D-Phe;
- C is optionally substituted D-Trp, D-Thi or D-Pal(3);
- D is Tyr, Arg or His;
- E is D-Ser(R.sup.1), D-Thi or the radical of the D-amino acid of the formula II;
- F is Ser(R.sup.1), Leu, Phe or Trp and
- G is Gly-NH.sub.2, D-Ala-NH.sub.2, Aza-Gly-NH.sub.2 or NH-(C.sub.1 -C.sub.4)-alkyl and
- R.sup.1 and R.sup.2 are as defined in claim 1;
- or a physiologically acceptable salt thereof.
- 4. A peptide of the formula I as claimed in claim 3, wherein
- X is (C.sub.1 -C.sub.7)-acyl,
- A is D-Nal(2);
- B is D-Phe(Cl);
- C is D-Trp;
- D is Tyr, His or Arg;
- E is D-Ser(R.sup.1);
- F is Ser(R.sup.1), Leu, Phe or Trp and
- G is D-Ala-NH.sub.2 or Aza-Gly-NH.sub.2 and
- R.sup.1 and R.sup.2 are as defined in claim 1,
- or a physiologically acceptable salt thereof.
- 5. A peptide of the formula I as claimed in claim 1, wherein R.sup.1 represents an unprotected glycosyl radical, or a physiologically acceptable salt thereof.
- 6. A method for the treatment of fertility, which comprises the administration of an effective amount of a peptide as claimed in claim 1 or a physiologically acceptable salt thereof.
- 7. A method for the treatment of diseases dependent upon gonadotropin, testosterone and estrogen, which comprises the administration of an effective amount of a peptide as claimed in claim 1 or a physiologically acceptable salt thereof.
- 8. A method for the treatment of steroid-dependent diseases, which comprises the administration of an effective amount of a peptide as claimed in claim 1 or a physiologically acceptable salt thereof.
- 9. A pharmaceutical composition for the treatment of fertility, comprising an effective amount of a peptide as claimed in claim 1 or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 10. A pharmaceutical composition for the treatment of diseases dependent on gonadotropin, testosterone and estrogen, comprising an effective amount of a peptide as claimed in claim 1 or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 11. A pharmaceutical composition for the treatment of steroid-dependent diseases, comprising an effective amount of a peptide as claimed in claim 1 or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3634435 |
Oct 1986 |
DEX |
|
Parent Case Info
This application is a continuation of application Ser. No. 390,477, filed Aug. 7, 1989, now abandoned, which is a continuation of application Ser. No. 105,240, filed Oct. 7, 1987, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4472382 |
Labrie et al. |
Sep 1984 |
|
4728640 |
Labrie et al. |
Mar 1988 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
2465486 |
Mar 1981 |
FRX |
188987 |
Feb 1982 |
NZX |
200125 |
Oct 1984 |
NZX |
204692 |
Mar 1986 |
NZX |
Non-Patent Literature Citations (2)
Entry |
Chem. Abstr., vol. 110, 58099v (1989). |
Synthesis of a Glycotripeptide and a Glycosomatostatin Containing the 3-O-(2-Acetamido-2-Deoxy-.beta.-D-Glucopyranosyl)-L-Serine Residue. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
390477 |
Aug 1989 |
|
Parent |
105240 |
Oct 1987 |
|